Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at UBS Group

UBS Group upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a strong-buy rating in a report released on Wednesday,Zacks reports.

A number of other equities research analysts have also weighed in on ARWR. Stifel Nicolaus initiated coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $99.07.

Arrowhead Pharmaceuticals Stock Down 4.4%

Shares of Arrowhead Pharmaceuticals stock traded down $2.60 during trading hours on Wednesday, hitting $55.90. 1,772,723 shares of the company’s stock traded hands, compared to its average volume of 2,220,603. Arrowhead Pharmaceuticals has a twelve month low of $36.57 and a twelve month high of $95.49. The company has a market cap of $7.87 billion, a PE ratio of -24.84 and a beta of 1.29. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock has a 50 day simple moving average of $75.53 and a 200-day simple moving average of $75.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company’s revenue was up 171.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.26) EPS. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Optiver Holding B.V. raised its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $39,000. Finally, Allied Private Wealth LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $43,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported interim Phase 1/2a results for ARO-MAPT, its investigational Alzheimer’s treatment. The drug reportedly crossed the blood-brain barrier and produced up to a 73% reduction in tau, a protein associated with Alzheimer’s disease. The results support the potential of Arrowhead’s TRiM platform for delivering RNA therapies into the central nervous system. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: UBS initiated coverage of ARWR with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reiterated Buy ratings with targets of $115 and $120, respectively. The targets reflect analysts’ confidence in Arrowhead’s pipeline and potential long-term upside. Arrowhead Pharmaceuticals Receives a New Rating from UBS
• Positive Sentiment: HC Wainwright projects Arrowhead could earn $9.61 per share in fiscal 2031, a sharp contrast with the expected loss of $3.62 per share for the current fiscal year. This highlights the firm’s view that commercialization of Arrowhead’s pipeline could significantly improve future profitability.
• Neutral Sentiment: The ARO-MAPT findings are interim, early-stage results and will require confirmation in larger, later-stage trials before they can support regulatory approval or commercial revenue.
• Negative Sentiment: After the initial data-driven surge, investors may be taking profits and reassessing valuation. Arrowhead remains unprofitable, recently missed quarterly EPS expectations, and faces substantial clinical, regulatory, and execution risks.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.